Consequently, BTK inhibition as a therapeutic strategy to control underlying mechanisms contributing to MS progression may be particularly effective via its dual actions on microglia and CNS B cells, downregulating microglia activation directly and in addition reducing the production of microglia-activating IgG. Here, BTK is linked to myeloid sarcoma.